Compound Therapeutics Announces Initiation Of IND-enabling Safety Studies With Lead Oncology Product; First Of A New Class Of Protein Therapeutics
10/19/2005 5:09:19 PM
WALTHAM, Mass.--(BUSINESS WIRE)--June 22, 2005--Compound Therapeutics announced that it has initiated IND-enabling animal safety studies with CT-322, its lead product. CT-322 is an AdNectin blocker of vascular endothelial growth factor receptor-2 (VEGFR-2), a receptor that is the key driver of angiogenesis. Inhibition of this biological pathway has been demonstrated to be highly effective in treating many cancers, as well as in treating age-related macular degeneration (AMD).
"AdNectins represent the future of protein therapeutics, and CT-322 is the first of numerous products in our pipeline," said Dr. John Mendlein, Chief Executive Officer. "The fact that the company achieved this landmark less than a year from identifying the molecule itself is an excellent demonstration of the power of our product engine. Our GLP safety study is a critical milestone, not only in the development of this important oncology product, but also in the acceleration of AdNectins as a breakthrough class of therapeutics."
comments powered by